Table 2.

Patient characteristics

	BRCA group, n = 43	Control group, n = 174
Female age (mean, SD)	31.4 ± 3.7	32.1 ± 4.1
Female BMI (mean, SD)	23.8 ± 3.0	23.9 ± 3.5
AD disorders (n, %)	43 (100.0)	119 (68.4)
Female carriers	42	59a
Male carriers	n/a	57
Both partners	1	3
BRCA1 (n, %)	20 (46.5)	n/a
BRCA2 (n, %)	22 (51.2)	n/a
BRCA2 female + retinoblastoma male (n, %)	1 (2.3)	n/a
Huntington’s disease	n/a	25b
Neurofibromatosis type 1	n/a	12c
Myotonic dystrophy type 1d	n/a	10
Familial adenomatous polyposis	n/a	10
Spinocerebellar ataxia type 3	n/a	8
Marfan syndrome	n/a	7
Other	n/a	47e
AR disorders (n, %)	n/a	55 (31.6)
Cystic fibrosis	n/a	16
Spinal muscular atrophy	n/a	13e
Other	n/a	26

SD standard deviation, BMI body mass index, AD autosomal dominant, AR autosomal recessive, n/a not applicable

^aOne woman had both Peutz-Jeghers syndrome and porencephalia

^bOf which five couples opted for exclusion PGD

^cOf which two couples had two indications for PGD

^dOnly males with myotonic dystrophy type 1 were included, since myotonic dystrophy type 1 is potentially associated with a reduced ovarian reserve

^eOf which one couple had two indications for PGD